Product Description: Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.
Applications: Metabolism-sugar/lipid metabolism
Formula: C22H18Cl2N8
References: [1]Li X, et al. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. Cell Stem Cell. 2015;17(2):195-203. /[2]Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605(7909):325-331. /[3]Cao N, et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science. 2016;352(6290):1216-1220. /[4]Choi IY, et al. Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Rep. 2016;15(10):2301-2312. /[5]Bar-Nur O, et al. Direct Reprogramming of Mouse Fibroblasts into Functional Skeletal Muscle Progenitors. Stem Cell Reports. 2018 May 8;10(5):1505-1521. /[6]Zhao J, et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat Med. 2022 Feb;28(2):272-282.
CAS Number: 252917-06-9
Molecular Weight: 465.34
Research Area: Cancer; Metabolic Disease
Solubility: 10 mM in DMSO
Target: Autophagy;GSK-3;Wnt;β-catenin
English
Deutsch
